Humanigen Inc (HGENQ)

[DonDonDonDon]

Humanigen’s Budget Impact Model Demonstrates Lenzilumab’s Potential Positive Economic Value in Hospitalized COVID-19 Patients

Oct 11, 2021

https://ir.humanigen.com/English/news/news-details/2021/Humanigens-Budget-Impact-Model-Demonstrates-Lenzilumabs-Potential-Positive-Economic-Value-in-Hospitalized-COVID-19-Patients/default.aspx

*Overall analysis demonstrates treatment with lenzilumab may result in both clinical and economic benefits in the majority of hospitalized patients

*Potential clinical and economic benefits are greater in certain patient populations

BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that a manuscript describing its budget impact model for the treatment of patients hospitalized with COVID-19 is available on medRxiv (link). These results highlight the value of selecting the right treatment for the right hospitalized patients during this time of unprecedented pressure on health systems.

The cost to care for a COVID-19 patient in the ICU can significantly exceed $100,000 and average costs for patients on invasive mechanical ventilation in ICU amount to $78,245 per patient.1 Lenzilumab is an investigational product and is not currently authorized or approved in any country.